Injection
Tesamorelin
A peptide that targets stubborn abdominal fat and supports a leaner body composition, prescribed and monitored by a licensed clinician.
Starting at $179/mo
Growth hormoneRecovery & sleep
Tesamorelin / Ipamorelin
RxPrescription onlyInjected under the skin · 5 days a week · 0.6 mg · Growth hormone · Recovery & sleep
Starting at $229/mo
Tesamorelin and ipamorelin together: two complementary signals that encourage your own growth hormone for sleep, recovery, and abdominal fat reduction.
Choose your plan
Real prices from our pharmacy. Longer plans cost less per month and are billed up front. Pause or cancel anytime.
- Two pathways to your own growth hormone in one injection
- Tesamorelin is studied specifically for visceral fat
- Nightly subcutaneous injection, dosed by your physician
Every plan includes
- Personalized, physician-guided plan
- Monthly, 3-month and 6-month plans
- Dispensed by a US-licensed compounding pharmacy
- Unlimited protocol adjustments and messaging
- Ongoing support and check-ins
- Pause or cancel anytime
- Reviewed by our in-house physicians
- Physician-guided care
- Ongoing, expert support
- 100% online
- Free, discreet shipping
What is Tesamorelin / Ipamorelin?
(a GHRH analog with a selective secretagogue)
Tesamorelin is a growth hormone-releasing hormone that raises your own growth hormone pulses; it has the strongest evidence of any GH peptide for reducing deep abdominal (visceral) fat. Ipamorelin works through a second receptor to release growth hormone selectively, without raising cortisol or prolactin. Together they amplify your natural growth-hormone rhythm.
- How it is taken
- Injected under the skin
- How often
- 5 days a week
- Dose range
- 0.6 mg
- Form
- Growth hormone · Recovery & sleep
Randomized
human trials for tesamorelin and visceral fat reduction
Tesamorelin reduced visceral fat and liver fat in controlled trials. Ipamorelin evidence is from pharmacology studies. The combination is prescribed off-label at your physician's discretion.
How it works,
week by week.
Day 1
A US-licensed physician reviews your goal, health history and reasons to try this early-stage peptide. You discuss the evidence and the unknowns together.
Week 1
A small subcutaneous injection, usually in the abdomen or near the site you're treating. Most people find the routine comfortable within days.
Week 2–4
Signaling and recovery processes begin. Many report improved energy or easier movement, depending on the peptide.
Month 2+
Your physician checks in, adjusts dose if needed, and follows relevant labs (IGF-1, immune markers, etc.). Tell them everything you notice.
What you may notice,
and when.
Slower feedback
early-stage therapies take time and close monitoring
Individual response
outcomes vary widely because evidence is limited
Physician partnership
your role is to communicate closely at every check-in
Informed choice
you understand the evidence gap before starting
Individual results vary. Benefits reflect what Zepym Health members commonly report to their physician at check-ins; they are not the results of a clinical trial.
Safety first:
what to know before you start.
Important safety information and common side effects
Research peptides are prescribed off-label and carry more uncertainty than established therapies. Common, mild effects include redness, itching or a bump at the injection site, headache, or flushing in the first days. Because these peptides support cell growth or immune signaling, they are not prescribed with an active cancer, a cancer under evaluation, or during pregnancy or breastfeeding. Some (IGF-1) require careful glucose monitoring. Tell your physician about every medication you take, every supplement, and your complete health history, including any autoimmune conditions. Stop and seek care for hives, swelling of the face or lips, or trouble breathing.
The research behind
tesamorelin.
A GHRH analogue with a current FDA label for excess abdominal fat in adults with HIV-associated lipodystrophy. It has randomized trials in people, the largest in 412 adults with HIV, but only for that narrow use.
- HIV belly fatabout 15% less visceral fat
In 412 adults with HIV and excess abdominal fat, 2 mg injected daily for 26 weeks reduced visceral fat by about 15%. Most participants (86%) were men.
Falutz et al., N Engl J Med 2007 - FDA labelone approved use
The US label (EGRIFTA WR and SV, revised March 2025) is for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It says long-term cardiovascular safety has not been established and that the drug is not indicated for weight loss.
EGRIFTA WR and SV prescribing information, FDA - Cognitionsmall older-adult trial
Baker et al. (Arch Neurol 2012) gave tesamorelin 1 mg at bedtime for 20 weeks to 152 adults aged 55 to 87, 66 of them with mild cognitive impairment. Cognition improved more than on placebo across the group, most clearly for executive function.
Baker et al., Arch Neurol 2012
What the studies found
- Reduces visceral (deep abdominal) fat by about 15% over 26 weeks in adults with HIV and excess belly fat (Falutz, NEJM 2007)
- Lowers triglycerides by about 50 mg/dL over 26 weeks, while placebo raised them by about 9 mg/dL, in the same HIV trial (Falutz, NEJM 2007)
- Approved by the FDA to reduce excess abdominal fat in adults with HIV-associated lipodystrophy (EGRIFTA label, revised 2025)
- Better executive-function scores than placebo after 20 weeks in 152 older adults, 66 with mild cognitive impairment (Baker, Arch Neurol 2012)
- Reduces percent body fat by 7.4% in the same older-adult trial (Baker, Arch Neurol 2012)
The HIV trials used the 2 mg daily dose of the 1 mg-per-vial formulation, which the label describes as EGRIFTA WR. The benefit is for fat in one area, not for general weight or health. Compounded or research-grade tesamorelin was not the product studied.
What this does not say
- Approved use is limited to HIV-associated abdominal fat; it is not approved for weight loss or longevity.
- The label warns of an increased risk of neoplasms (cancer) and says long-term cardiovascular safety has not been established.
- IGF-1 rises during treatment, and the label says the effects of prolonged elevation are unknown.
- The ipamorelin partner in the blend has only the evidence on its own page; the combination was not tested together.
The research
behind it.
In randomized trials in adults with HIV, tesamorelin reduced visceral abdominal fat by about 15% over six months and lowered liver fat, working through the body's own GH release.
Ipamorelin adds selective GH release. Your physician monitors IGF-1, lipids and how you feel at check-ins, adjusting dose as needed.
Getting started
takes a few minutes.
- 1
Connect with a physician
Answer a few questions online and a US-licensed physician reviews your health, history and goals to make sure treatment is right for you. 100% online. No in-person visit required.
- 2
Get your discreet shipment
If approved, your treatment is compounded by a US-licensed, LegitScript-certified pharmacy, inspected for quality, and shipped discreetly to your door.
- 3
Receive continuous support
Start with one goal, then keep building over time. Unlimited physician messaging, easy refills and dose adjustments, all from the Zepym Health app.
Frequently asked questions
Contact supportHow do I use Tesamorelin / Ipamorelin?
Injected under the skin, 5 days a week, at bedtime. The starting prescription is 20 units (0.6 mg) each time. Your physician sets your own dose and it is printed on your label.
What exactly is in it?
Tesamorelin, Ipamorelin.
How much arrives in each shipment?
1 vial at the starting strength, shipped to your door from a licensed US pharmacy.
Why combine tesamorelin with ipamorelin?
Tesamorelin has strong evidence for visceral fat; ipamorelin adds a second GH pathway. Together they are chosen when abdominal fat, sleep and recovery are the goals. If weight loss alone is the goal, your physician may recommend a GLP-1 instead.
Why are these off-label?
Off-label means not FDA-approved for these specific uses, but prescribed by physicians based on preclinical evidence and clinical experience. It is common in medical practice; your physician explains the evidence and the gaps.
How often do I take it?
Usually a small subcutaneous injection once daily or a few times a week, depending on the peptide. Your physician sets the schedule and adjusts it as needed. The kit includes everything.
What is the evidence really like?
Honest answer: early. Preclinical and animal data are promising; human data are limited or absent. Your physician explains this plainly and monitors you closely. If you prefer established therapies, tell them.
Tesamorelin / Ipamorelin educational content reviewed by our physician
Scott Nass, MD Doctor of Medicine, board-certified in Family Medicine
Charles R. Drew University and David Geffen School of Medicine at UCLA. Family Medicine residency at Ventura County Medical Center.
More options
in this area.
Troche
Sermorelin Troches
The same growth hormone-releasing peptide as a dissolving troche, for people who would rather skip injections.
30 troches per month
Starting at $209/mo
Injection
CJC-1295 / Ipamorelin
Two peptides that prompt your pituitary to release your own growth hormone, used for deeper sleep, recovery and body composition. Prescribed and dosed by a licensed physician.
Starting at $229/mo
Injection
BPC-157
A peptide studied for tissue repair and recovery, used to support healing of muscle, tendon and gut after injury or hard training. Prescribed and dosed by a licensed physician.
Starting at $209/mo
References
- 1.Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells, 2020
- 2.Unique features of human cathelicidin LL-37. Biofactors, 2015
- 3.Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med, 2025
- 4.Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med, 2007
- 5.Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998
- 6.Thymosin alpha 1: A comprehensive review of the literature. World J Virol, 2020
Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate. Products are compounded by a licensed pharmacy. The FDA has not reviewed or approved compounded products for any use for safety, efficacy, or quality. Compounded medications are not FDA-approved brand-name products.